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Cardiovascular Injury and Repair in Chronic Obstructive
Pulmonary Disease
William MacNee1, John Maclay1, and David McAllister1
1ELEGI Colt Laboratories, MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom
Cardiovascular disease represents a considerable burden in terms of
both morbidity and mortality in patients with chronic obstructive
pulmonarydisease(COPD).For20years, forcedexpiratoryvolume in
1 second (FEV1) has been an established predictor of cardiovascular
mortality among smokers, never-smokers, and patients with COPD.
We review evidence for increased cardiovascular risk in COPD. In
addition, we assess the emerging evidence which suggests that
hypoxia, systemic inflammation, andoxidative stress inpatientswith
COPDmay cause cardiovascular disease. We also discuss alternative
hypotheses that the endothelium and connective tissues in the
arteries and lungs of patients with COPD and cardiovascular disease
have a shared susceptibility to these factors.
Keywords: COPD; cardiovascular disease; systemic inflammation;
endothelial dysfunction
Chronic obstructive pulmonary disease (COPD) is a chronic
inflammatory disease of the lungs with a complex pathology
involving large (chronic bronchitis) and small (bronchiolitis)
airways, lung parenchyma (emphysema), and the pulmonary
vasculature. In addition to pathology in the lungs, COPD is now
believed to have systemic features (1, 2), and this has been
recognized in the definition of COPD in recent guidelines (3,
4). An increase in the risk of cardiovascular disease is one such
systemic feature (5). There is now considerable evidence of an
association between COPD and cardiovascular disease, which
will be reviewed in this article, together with the mechanisms
which may underlie this association.
AIRFLOW LIMITATION AND CARDIOVASCULAR RISK
A number of population studies have shown that FEV1 is a pre-
dictor of cardiovascular risk, even after adjusting for known
cardiovascular risk factors such as age, sex, smoking, cholesterol,
and education level/social class (Table 1) (6). In the Third
National Health and Nutrition Examination Survey (NHANES
III), 1,861 subjects who were 40 to 60 years of age at baseline
assessment were followed and their cardiovascular mortality
assessed. The group in the lowest quintile for FEV1 had the
highest risk of cardiovascular mortality (relative risk [RR], 3.36;
95% confidence interval [CI], 1.54–7.34) and had a fivefold
increase in the risk of death from ischemic heart disease,
compared with the quintile with the highest FEV1. Similar
relationships between FEV1 and cardiovascular mortality have
been shown in other large cohort studies, including the Framing-
ham Heart Study and the Copenhagen City Heart study (6–11)
(Table 1). Moreover, reduced FEV1/FVC ratio, which is a more
specific indicator of airflow limitation than FEV1, is also an
independent risk factor for coronary events (RR, 1.30) (12).
There appears to be no threshold in the relationship between
cardiovascular risk and FEV1; indeed, FEV1% predicted is
associated with cardiovascular risk even in never-smokers (8).
There is also a relationship between the rate of decline in
FEV1 and cardiovascular disease. In the Malmo ‘‘men born in
1914 study,’’ there were 56 cardiovascular events per 1,000
person-years in smokers in the highest tertile of decline in FEV1,
and 22.7 in the groupwith the lowest tertile (12, 13). TheBaltimore
Longitudinal Study of Ageing (14) showed that those individuals
who had themost rapid decline in FEV1 over a follow-up period of
16 years were three to five times more likely to die from a cardiac
cause than those who had the slowest decline in FEV1. This
association was also found even among lifetime nonsmokers,
suggesting that the relationship between change in FEV1 and
cardiovascular events is independent of the effects of smoking. In
addition, NHANES III patients with severe airflow limitation
(defined as an FEV1, 50% predicted and an FEV1/FVC ratio<
70%) were 2.1 times more likely to have electrocardiographic
evidence suggestive of a prior myocardial infarction (5).
The FEV1 is also an independent predictor of cardiovascular
mortality in COPD. The Lung Health Study reported that for
every 10% decrease in FEV1, there was an increase of approx-
imately 28% in fatal coronary events, and 20% in nonfatal coro-
nary events, among subjects with mild to moderate COPD (15).
However, low FEV1 is not specifically associated with risk
from cardiovascular disease. Indeed, low baseline FEV1 predicts
strokemortality (16), aswell all-cause cancermortality, anddeath
from nonrespiratory, noncardiovascular causes (8). As such,
FEV1 may simply be a marker of exposure to a wide range of
determinants of health that are difficult to adjust for statistically,
such as poor nutrition and exposure to environmental pollution
(including second-hand smoke). However, another possibility is
that individuals with lower FEV1 might have an enhanced
inflammatory response to such stimuli, increased susceptibility
to inflammation, or impaired healing. Only a proportion of
individuals, even with significant cigarette smoke exposure, de-
velopCOPD (17), and similar hypotheses have been suggested to
explain this observation (18).
CARDIOVASCULAR MORTALITY AND MORBIDITY
IN COPD
Cardiovascularmortality is a leading, but underrecognized, cause
of death in patients with COPD. In the Tucson Epidemiological
Study of Airways Obstructive Disease (19), nearly 50% of those
patients in whom obstructive airways disease was mentioned as
a contributing cause of death had a cardiovascular cause as the
primary cause. In a healthcare database study, which included
11,493 COPD patients followed up over 3 years, a three- to
fourfold increasedmortality rate from cardiovascular diseasewas
found in patients with COPD (RR, 2.07; 95% CI, 1.82–2.36),
compared with age- and sex-matched control subjects without
COPD. Patients with COPD had a higher risk of congestive
cardiac failure (RR, 4.09), arrhythmia (RR, 2.81), and acute
myocardial infarction (RR, 1.51) (20).
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In patients with established cardiovascular disease, COPD is
associated with increased cardiovascular mortality. In a study of
4,284 patients who received treatment for coronary heart disease,
mortality rates of 21% were noted over a 3-year follow up in
patients diagnosed with COPD, compared with 9% in those
without co-existing COPD (21). In an observational prospective
study in patients after an acute myocardial infarction, 1-year
mortality and re-hospitalization rates were significantly higher in
patients with than in those without COPD (15.8% versus 5.7%
and 48.7% versus 38.6%, respectively) (22). Furthermore,
patients hospitalized for heart failure who also have COPD have
a poorer prognosis, with an excessmortality, comparedwith heart
failure patients without COPD (23).
Moreover, there is a higher riskof cardiovascularmorbidity and
hospitalization for cardiovascular disease in patients with COPD.
In a retrospective matched cohort study from the Northern
California Kaiser Permanent Medical Care Program involving
40,966 patients with COPD diagnosed between 1996 and 1999, the
risk for hospitalization and cardiovascular disease was higher in
patients with COPD (RR, 2.09; 95% CI, 1.99–2.20), than in age-
and sex-matched control subjects (24). Younger patients (aged ,
65 yr) and female patients had higher risk than older male
participants. A further study from the Saskatchewan Health
Service Database of 5,648 newly treated patients with COPD >
55 years old, between 1990 and 1999, showed that cardiovascular
morbidityandmortalitywerehigher inpatientswithCOPDthan in
the general population (RR, 1.9 and 2.0, respectively) (25).
In these studies morbidity and mortality data were obtained
from routine data sources such as death certificates, which can
lead to diagnostic misclassification. However, in the Toward
a Revolution in COPD Health (TORCH) trial, a large study of
the effects of inhaled corticosteroids and long-acting b-agonists
on mortality in COPD, where cause of death was accurately
assessed by an adjudication panel, 25% of deaths were diagnosed
as due to pulmonary causes and 27% to cardiovascular disease
(26). Similarly, in the Lung Health Study an independent
mortality and morbidity review board established cause of death
and hospitalization in 5,887 patients with COPD aged 35 to 46
with mild to moderate airways obstruction over 5 years. This
cohort had a 5-year mortality of 2.5%; of this, 25% died of
a cardiovascular event, and cardiovascular disease accounted for
42% of the first hospitalization and 44% of the second hospital-
ization over a follow-up period in patients with relatively mild
COPD, compared with 14% of hospitalization from respiratory
causes (15).
Thus, a range of general population studies and studies in
patients with COPD suggests that COPD may be an important
risk factor for ischemic heart disease and sudden cardiac death.
The mechanism responsible for the increased risk of cardiovas-
cular disease in patients with COPD is not known; however,
a number of hypotheses have been proposed (Figures 1 and 2).
SYSTEMIC INFLAMMATION AND CARDIOVASCULAR
RISK IN COPD
The pathophysiology of atherosclerosis is complex (27). The role
of lipid metabolism in atherosclerosis is long established. How-
ever, more recent studies have revealed the importance of
TABLE 1. SELECTED COHORT STUDIES PROVIDING EVIDENCE FOR AN ASSOCIATION BETWEEN FEV1 AND
CARDIOVASCULAR MORTALITY
Author
Sample
Size
Follow-up
(yr)
Mean
Age (yr) Lung Function Relationship Adjusted for
Hole (17) 15,411 15 44–64 FEV1 1st to 5th quintile
ranged from 73–113%
predicted
Increase in RR of 1.56 in
cardiovascular mortality
comparing highest
with lowest quintile
Age, smoking, serum cholesterol,
BMI, social classRenfrew, UK
Ebi-Kryston (16) 17,717 10 40–64 FEV1 , 65% Chronic phlegm production
associated with
all-causes and respiratory
disease mortality,
but not after adjusting
for reduced FEV1
Age, smoking, employment
grade, BP, antihypertensive
medication, cholesterol,
diabetes, ECG, IHD Hx.
Whitehall Study, UK
Schunneman (88) 1,195 29 47 FEV1 1st to 5th quintile
ranged from 80–114%
predicted
Increase in RR of 2.11 in
cardiovascular mortality
comparing highest with
lowest quintile
Age, smoking, BP, BMI,
education statusBuffalo Study, US
Persson (18) 1,462 12 38–60 PEFR 123–545 L  min21 PEFR inversely proportional
to risk of death from
myocardial infarction
Age, height, BMI, waist/hip
ratio, chest deformity,
pulmonary disease, smoking,
lipid levels, BP, diabetes,
and physical activity
Sweden, Europe
Truelsen (19) 12,878 up to 17 45–84 FEV1 808 strokes RR 1.05 for each
10% decrease in FEV1%
predicted. Similar risk for
stroke mortality
Sex, age, smoking, inhalation,
BMI, systolic blood pressure,
triglycerides, physical activity
in leisure time, education,
diabetes mellitus, and
antihypertensive treatment
Copenhagen City
Heart study, Europe
Hozawa (25) 13,842 Up to 13 45–64 FEV1 percent predicted
quartiles
Relative hazards 1.59, 1.52,
1.26, and 1.00 for each
quartile of FEV1% predicted,
in White Americans, no
association in African
Americans
Age, sex, race, education,
smoking status, BMI, WHR,
vWF, ethanol intake, HDL
cholesterol, systolic BP,
antihypertensive medication,
diabetes, WBC count and
fibrinogen. Association not
found in African Americans.
Atherosclerosis Risk In
Communities Study, US
Definition of abbreviations: BMI 5 body mass index; BP 5 blood pressure; HDL 5 high-density lipoprotein; PEFR 5 peak expiratory flow rate; RR 5 relative risk; vWF 5
von Willebrand factor; WBC 5 white blood cell; WHR 5 waist/hip ratio.
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inflammation in plaque initiation, development, and rupture (28–
30). The atherosclerotic process starts with injury to the vascular
endothelium, which is made more permeable by a variety of
factors, including systemic inflammation and oxidative stress.
Lipoproteins then enter the intima via the vascular endothelium.
Modified lipoproteins and systemic oxidative stress and inflam-
mation induce cytokineproduction and increase the expressionof
cell adhesion molecules, such as ICAM-1 and VCAM-1, on the
vascular endothelium, allowing circulating white blood cells to
adhere to damaged endothelial surfaces. The release of chemo-
taxins directsmigration of these leukocytes to the vascular intima.
In this inflammatory environment, there is increased expression
of scavenger receptors on monocytes/macrophages that ingest
modified lipid lipoprotein particles, promoting the development
of foam cells. Vascular smooth muscle cells then proliferate and
may migrate from the media into the intima. These muscle cells
produce extracellular matrix, which accumulates in the plaque
with the formation of fibro-fatty lesions. This results in vessel wall
fibrosis and consequent smooth muscle cell death. Calcification
may occur, producing a plaque with a fibrous cap surrounding
a lipid-rich core.
A number of cells and molecules can both promote and
amplify this inflammatory process. Activated T-lymphocytes
andmacrophages can stimulate the release of cytokines, resulting
in endothelial activation. In addition to an increased expressionof
adhesion molecules on activated endothelium, cytokines such as
interleukin (IL)-1, IL-6, and tumor necrosis factora (TNF-a) can
facilitate the deposition of components of atheromatous plaque
formation. C-reactive protein (CRP) is an acute phase protein
primarily produced by hepatocytes under the stimulation of IL-6
that is released after vascular damage. CRP, when released into
the circulation, can up-regulate other inflammatory cytokines,
activate complement, and promote the uptake of low density
lipoproteins bymacrophages. CRPalso interacts with endothelial
cells to stimulate the production of IL-6 and endothelin-1 (31, 32).
Stable atherosclerotic plaques are characterized by a thick
fibrous cap and relatively little lipid accumulation. They progress
relatively slowly and occlude the vessel lumen, resulting in angina
pectoris. Vulnerable plaques, which contain large amounts of
lipid and inflammatory cells, have a thin fibrous cap and are prone
to rupture. After plaque rupture, lipids leak on to the arterial
lumen and produce vasoconstriction and thrombus formation.
The development of thrombus on a ruptured plaque is dependent
on the fibrinolytic balance between the release of tissue type
Plasminogen Activator (tPA) and Plasminogen Activator In-
hibitor-1 (PAI-1).
The amount of thrombus formation determines the develop-
ment of acute coronary syndromes in response to plaque rupture.
In most cases, plaque rupture occurs asymptomatically, since
there is a fibrinolytic excess preventing the formation of thrombus
(33). Systemic inflammation may also affect this process, as
chronic smoking, passive smoking, and several inflammatory
mediators appear to acutely inhibit endothelial tPA release. Thus,
systemic inflammation is a potential mechanism in the develop-
ment of atherosclerosis, and in addition, increased systemic in-
flammatory responses (associated with, for example, infection) are
associated with acute cardiovascular events (34).
There is abundant evidence of increased systemic inflamma-
tion, both activated circulating leukocytes and increased inflam-
matory mediators in COPD (35). The origin of the systemic
inflammatory response inCOPDhas not been clearly established,
but a number of mechanisms have been proposed (reviewed in
References 1 and 2). These include direct ‘‘spillover’’ of lung
inflammation to the systemic circulation, an effect of lung
hyperinflation, tissue hypoxia, muscle dysfunction, and bone
marrow stimulation. Peripheral blood neutrophils are activated
in patients with COPD to release reactive oxygen species (36),
have increased expression of adhesion molecules (37), and
demonstrate enhanced chemotaxis and extracellular proteolysis,
mechanisms that are involved in the pathogenesis of atheroscle-
rosis. For example, circulating monocytes from patients with
COPD release 2.5-fold greater amounts of matrix metalloprotei-
nase-9 (MMP9) than control subjects (38), and MMP9 has been
implicated in the pathogenesis of arteriosclerosis and in plaque
rupture (28).
Figure 2. Putative mecha-
nisms linking coronary
heart disease and chronic
obstructive pulmonary dis-
ease. hsCRP 5 high-sensi-
tivity C-reactive protein; IL-
6 5 interleukin-6; MMPs 5
matrix metalloproteases;
NO 5 nitric oxide; ROS 5
reactive oxygen species;
TNF-a5 tumornecrosis fac-
tor a; tPA 5 tissue plasmin-
ogen activator.
Figure 1. Pathophysiology in chronic obstructive pulmonary disease
and coronary heart disease.
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CRP is a biomarker of systemic inflammation. In addition, it is
a marker of increasedmortality in both COPD and in the general
population (39), and is also a marker of increased cardiovascular
risk (40). CRP is also found in atheromatous lesions and may
therefore have a causal role in atherogenesis (41). Studies in vitro
have shown that CRP adversely affects vasomotor endothelial
function through the inhibition of endothelial nitric oxide syn-
thase and consequently the production of nitric oxide (NO).
Endothelial fibrinolysis is also impaired by CRP, which induces
the production of PAI-1 (42, 43). A number of other inflamma-
tory biomarkers have also been implicated in plaque formation,
such as IL-7, IL-8, TNF-a, and fibrinogen (44–46).
A large number of studies have shown increases in circulating
CRP levels in patients with COPD, which occurs with increased
frequency as the disease progresses (47). In stable COPD there is
an inverse relationship between CRP and airflow limitation, 6-
minute walking distance, and bodymass index (5, 39). An inverse
relationship also exists between CRP concentrations and meas-
ures of pulmonary function in subjectswithout pulmonary disease
and in never-smokers (48). There is an interaction between
cigarette smoking and lung function on CRP levels. In the
NHANES study the odds ratio of having an elevated CRP was
increased in smokers and in subjects with a low FEV1. However,
the presence of smoking and a low FEV1 increased the odds ratio
of having an increased CRP even higher (49).
The Framingham Risk Score, the most widely used tool for
predicting risk of cardiovascular events, is improved by adding
CRP to the prediction models (50). In the NHANES study the
severity of airflow limitation and the CRP were related to the
cardiac infarction injury score (CIIS) (50). The CIIS is an
electrocardiographic coding scheme to assess cardiac injury and
is related to cardiovascularmortality (51). In this study the cohort
was divided according to the degree of airflow limitation (none,
mild, moderate, and severe) and the groups matched for lipid
profile, although blood pressure and smoking history were higher
in those with severe airflow obstruction. Patients with more
severe airflow limitation hadboth a higherCRP level and a higher
CIIS. The presence of severe airflow limitation and high CRP
were associated with an even higher CIIS (5).
The level of the CRP also relates to outcomes in COPD. In
a cohort of 1,302 individuals with airflow limitation, selected from
theCopenhagenCityHeart Study, individuals with baseline CRP
greater than 3mg/L had a higher risk of hospitalization and death
fromCOPD (hazard ratios 1.4, 25%CI, 1.0–2.0; and 2.2, 25%CI,
1.2–3.9, respectively), compared with individuals with a baseline
CRP less than or equal to 3 mg/L adjusted for age, sex, FEV1%
predicted, tobacco consumption, and ischemic heart disease (52).
Systemic inflammation is also associated with atheroma burden
and increased cardiovascular risk, as well as with endothelial
dysfunction after myocardial infarction. However, it remains
unclear whether systemic inflammation is a cause of cardiovas-
cular disease, or merely a marker.
SYSTEMIC OXIDATIVE STRESS IN COPD AND
CARDIOVASCULAR DISEASE
No studies have directly assessed the hypothesis that increased
systemic oxidative stress in COPD produces increased cardio-
vascular risk. Age, sex, obesity, cigarette smoking, hypertension,
diabetes mellitus, and dyslipidemias are known risk factors for
atherosclerosiswhich impair endothelial function, smoothmuscle
function, and vessel wall metabolism. These risk factors are
associated with increased systemic oxidative stress (53). It is
recognized that oxidative stress plays a pivotal role in the
pathogenesis of atherosclerosis, particularly its detrimental ef-
fects on vascular endothelial function (54).
Reactive oxygen species (ROS), particularly oxygen radicals,
injure cell membranes and nuclei and interact with endogenous
vasoactive mediators formed in endothelial cells and so modu-
late vasomotion and the atherogenic process. ROS also cause
lipid peroxidation, leading to the formation of oxidized lip-
oproteins (LDL), one of the key mediators of atheroscerosis.
Oxidized LDLs are involved in the development of atheroscle-
rosis by a number of mechanisms. They cause cholesterol ester
accumulation in macrophages, and by their cytotoxic actions on
monocytes cause inhibition of macrophage motility (55). Oxi-
dized LDLs also cause up-regulation of adhesion molecules on
the vascular endothelium leading to stimulation of monocytes,
macrophages, platelets, and T-lymphocytes in the endothelial
wall. ROS also mediate many of the responses to vascular
injury, such as the impairment of vessel tone, promotion of
inflammatory responses, leukocyte migration and adhesion, in-
creased smooth muscle cell migration, proliferation, and apo-
ptosis (56).
COPD has been associated with both local pulmonary and
systemic oxidative stress. Peripheral blood neutrophils har-
vested from patients with COPD produce more ROS than
those from normal subjects, and are associated with increased
plasma levels or nitrotyrosine and products of lipid peroxidation
as markers of oxidative stress (57). The increased oxidative
stress that occurs during exacerbations of COPD, together with
the enhanced systemic inflammatory response, have the po-
tential to increase plaque instability, leading to plaque rup-
ture, and may also alter fibrinolytic balance, making thrombosis
more likely after plaque rupture and consequent acute coronary
syndromes.
HYPOXIA AND CARDIOVASCULAR DISEASE
Patients with COPD are subject to hypoxia—either sustained
hypoxia in patients with severe disease and respiratory failure, or
intermittent hypoxia, for example during exercise or exacerba-
tions. However, there is a threshold effect for hypoxia in patients
with COPD related to the severity of the airflow limitation, which
does not apply to the relationship between pulmonary function
and cardiovascular risk. Hypoxia has been shown to have a
number of effects that influence atherogenesis. These include in-
creasing systemic inflammation and oxidative stress, up-regulating
cell adhesion molecules, and inducing hemodynamic stress
(58–60). Increased foam cell production, a critical constituent
of unstable atherosclerotic plaques, is also stimulated when
macrophages are exposed to hypoxic conditions (58). The
cellular adhesion molecules ICAM-1 and P-selectin have been
shown to be up-regulated by hypoxic challenge in human
umbilical endothelial cells (59), and CRP also increases in
response to hypoxic conditions (60). Hypoxia can also induce
increased oxidative stress. In an animal model, hypoxia pro-
duced atherosclerosis in the presence of dyslipidemia and
increased lipid peroxidation, a marker of oxidative stress (61),
and reduced levels of the antioxidant superoxide dismutase are
found in the myocardial tissue of rats exposed to hypoxic en-
vironments (62).
Hypoxia also induces hemodynamic stress (63). Normal sub-
jects exposed to an hypoxic challenge to reduce oxygen satura-
tions to 80% for 1 hour developed an increased heart rate and
cardiac index. These effects of acute and intermittent hypoxia
may have relevance for individuals with COPD, who are sub-
jected to intermittent hypoxic episodes during exertion and
exacerbations. Hypoxia also affects the renal circulation, re-
ducing renal blood flow and activating the renin angiotensin
system, resulting in increased peripheral vasoconstriction and
oxidative stress (64).
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EFFECTS ON THE SYMPATHETIC SYSTEM AND
CARDIOVASCULAR RISK
Activation of the sympathetic nervous system (SNS) is associated
with increased risk of cardiovascular disease (65), which, given
that both COPD and chronic respiratory failure are associated
with SNS activation (66), may contribute to the cardiovascular
morbidity and mortality observed in patients with COPD.
Several studies have found that a high resting heart rate is an
independent risk factor for CV morbidity and mortality in the
general population, and resting tachycardia is common in COPD
(67). Furthermore, COPD is also associated with reduced heart
rate variability, a marker of abnormal cardiac autonomic regu-
lation, which has been found to predict mortality in the elderly
(68, 69).
In view of the potential adverse effects of sympathetic
stimulation, and the beneficial effects of b-receptor antagonists
in heart failure, atrial fibrillation, and myocardial infarction,
several observational studies have examined the effects of b-
agonists on cardiovascular morbidity and mortality, with con-
flicting results (70–72).However, the recent TORCHstudy found
no increase in all-cause or cardiovascular mortality in 1,521
patients treated with salmeterol (a long-acting b-agonist), com-
pared with the 1,524 patients allocated to placebo (73).
In ameta-analysis including 131 patients with COPD random-
ized to either a cardioselective b-blockers or placebo, FEV1 was
not significantly different in patients treatedwithb-blockers (74).
Moreover, evidence from observational studies suggests that
cardioselective b-blockers reduce mortality in patients with
COPD after vascular surgery, myocardial infarction, or admis-
sion to hospital with acute exacerbation of COPD (75–77),
although in such studies it is difficult to avoid residual confound-
ing by disease severity. Nevertheless, there remains a reluctance
to use b-blockers in patients with COPD (78), despite the joint
recommendation of the American College of Cardiology and
American Heart Association that b-blockers should not be
routinely withheld in patients with COPDwho have heart failure
or a recent non ST-elevation myocardial infarction (79, 80).
VASCULAR DYSFUNCTION
Considerable interest has focused on the vasculature as a po-
tential explanatory mechanism for the association between
COPD and cardiovascular risk, with particular focus on endo-
thelial dysfunction and changes in arterial stiffness.
Central arterial stiffness, as measured by aortic pulse wave
velocity (PWV), has been shown to predict cardiovascular
mortality in longitudinal studies in a range of populations,
involving over 12,000 subjects in total, independent of age, sex,
smoking history, cholesterol, and mean arterial blood pressure.
PWV quantifies arterial stiffness bymeasuring the transit-time of
the pressure wave from the heart to the femoral artery. In healthy
compliant arteries there is a slow transit time for the wave, and in
stiffer arteries the pressurewavemovesmore quickly. PWVmore
closely reflects the pathologic state of central arteries and is better
associated with coronary atheroma burden and with known risk
factors such as smoking than peripheral blood pressure (81–83).
Arterial stiffness has been associated with airflow limitation.
Zureik and coworkers (84) found that PWV was associated with
FEV1 in 194 ostensibly healthy middle-aged men, independent
of age, sex, and smoking status, although Taneda and colleagues
(85) were unable to replicate this finding in 678 healthy
Japanese Americans. Therefore, reduced pulmonary function
may be associated with arterial stiffness in healthy individuals.
Sabit and coworkers (86) found that arterial stiffness was in-
creased in patients with COPD, compared with controls matched
for a number of cardiovascular risk factors, and that arterial
stiffness was higher in patients with more severe COPD than in
those with mild to moderate disease. Augmentation pressure (a
measure of central arterial pressure obtained via analysis of the
arterial wave form at the radial artery), was also found to be
increased in patients with COPD compared with healthy control
subjects matched for age, sex, and smoking history, independent
of co-existing cardiovascular morbidity (87). PWV is associated
withmarkers of systemic inflammation in healthy individuals (88)
and in patients with COPD. Sabit and colleagues (86) found
a correlation between IL-6 and aortic PWV, and Mills and
coworkers (87) showed a relationship between CRP concentra-
tions and augmentation pressure. Therefore, systemic inflamma-
tion may contribute to the increased arterial stiffness found in
patients with COPD.
One mechanism, by which systemic inflammation could
modify arterial function, is via the endothelium. Pulmonary
vascular endothelial dysfunction is well established in patients
with COPD (89), and there is recent evidence that endothelial
dysfunction may be abnormal in the systemic circulation. Barr
andcoworkers (90) found thatflow-mediateddilatation, amethod
for assessing endothelial function, was related to airflow obstruc-
tion in ex-smokers with and without COPD. Another potential
mechanism to explain the association proposed in this article was
that endothelial dysfunctionmight causeCOPDaswell as causing
cardiovascular disease in COPD, as the association between
FMD and FEV1 was not independent of CT measured emphy-
sema severity.
A further mechanism linking COPD to systemic arterial
abnormalities is the failure of repair both in the lungs and in the
vascular endothelium. Endothelial progenitor cells (EPCs) are
pluripotent stem cells derived from the bone marrow that
participate in vascular repair and angiogenesis, and a reduction
in EPCs has been implicated in atherothrombogenesis (91). Low
circulating endothelial progenitor cells predict future cardiovas-
cular events (92). Circulating EPCs are decreased in the systemic
vasculature of patients with COPD (93), although paradoxically
they appear to be increased in the pulmonary vasculature (94).
Reduced EPCs may result in a failure to repair vascular abnor-
malities.
CONNECTIVE TISSUE DEGRADATION
Emphysema severity, quantified by CT scanning, is also related
to brachial artery stiffness, independent of age, sex, and pack-
years smoked. In arteries, elastin degradation is associated with
increased collagen; larger, thicker arteries; and increased stiff-
ness (95). Similarly, elastin degradation in the lung leads to loss
of alveolar attachments, decreased compliance, increased col-
lagen, and emphysema (96). Skin wrinkling, which is character-
ized by elastin degradation in the dermis (elastosis) (97), has
also been found to be associated with CT emphysema severity,
independent of pack-years smoked (98).
Increased elastolytic activity has also been implicated in the
development of both arterial stiffness and emphysema severity.
A polymorphism in gelatinase B (MMP-9) is associated with
increased risk of arterial stiffness and is associated with upper
zone dominant emphysema (99). Increased levels of MMP-9 are
found both in bronchoalveolar lavage (100) and sputum (101) in
subjects with emphysema, and levels of MMP-9 are increased in
the serum of subjects with arterial stiffness (102). MMP-12
(macrophage elastase) knockout mice are protected against
cigarette smoke–induced emphysema compared with wild-type
mice (103), and MMP-12/apoE–deficient mice are protected
against elastin degradation in atherosclerosis compared with
single-deficiency apoE mice (104). Thus, enhanced proteolytic
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activity and subsequent elastin degradation could be the
mechanism linking emphysema and arterial wall stiffness.
It has also been proposed that autoimmunity in COPD might
be responsible for the systemic features of the condition (105).
Lee and colleagues (106) reported that patients with COPD and
emphysema, compared with control subjects without COPD
and emphysema, had increased B cell and T cell responses to
elastin peptides, as well as increased circulating antielastin
antibodies.
ACCELERATED AGING, ATHEROSCLEROSIS, AND COPD
Aging is an important determinant of both arterial stiffening
and the development of emphysema, and is also a key cause of
skin wrinkling and osteoporosis (107, 108). Consequently, there
has been some interest in aging as a mechanism of disease in
patients with COPD (109).
Although cigarette smoke exposure is the main cause of
COPD, individuals vary in their susceptibility to its effects.
COPD preferentially affects elderly individuals, with those
older than 65 years having a higher risk, independent of their
history of exposure to tobacco smoke. The reasons for this
remain unclear.
Many of the features of COPD are also seen with normal
aging among never-smokers. Progressive decline in lung func-
tion, a characteristic feature of COPD, also occurs with age in
healthy individuals (17). Aging lungs also show progressive
distal airspace enlargement, associated with elastin fibrin frag-
mentation and loss of elasticity, resulting in an emphysema-like
condition (107, 110).
Animal models of ageing produced by defects in ‘‘aging
genes,’’ such as senescence protein-30 (111) or klotho gene (112,
113), have a shortened lifespan and develop a syndrome re-
sembling accelerated aging with skin wrinkling, osteoporosis,
emphysema, and arterial stiffness (109). A similar phenotype is
found among patients with COPD. Therefore, COPD may be
a condition of accelerated aging.
Aging is characterized by shortening of the DNA component
of telomeres, the specialized segments located at the end of
eukaryotic chromosomes which protect them from degradation
and recombination (114). In most somatic cells telomeres
shorten with every cell cycle, and systemic oxidative stress
and inflammation enhance this shortening process (115).
Telomere length (TL) therefore reflects replication history of
cells, but is also a reflection of cumulative oxidative stress and
chronic inflammation acting on progenitor cells (116), and
provides a marker of biological age. Peripheral blood leukocytes
(PBL) are often used to measure TL in humans, and TL in blood
leukocytes also accords with that in other tissues (117). Shorter
telomeres in blood leukocytes correlate with a poor survival, due
principally to a higher mortality from heart and infectious
diseases (117–119). Interestingly, there is a dose-dependent
relationship between leukocyte telomere shortening and pack-
years smoked (120). Furthermore, alveolar epithelial and endo-
thelial cells from patients with emphysema exhibit greater
telomere shortening, compared with those from subjects without
emphysema. There is also evidence of increased markers of cell
senescence and apoptosis in alveolar cells as a consequence of
telomere shortening in emphysematous lungs (121). Cellular
senescence is associated with shortened or damaged telomeres
and is characterized by permanent exit from the cell cycle,
morphologic changes, and altered function. Senescent cells show
increased release of cytokines and chemokines and enhanced
matrix metalloprotease activity (122), which are potential mech-
anisms for the enhanced inflammation and tissue destruction in
emphysema. Accelerated aging, as measured by telomere short-
ening, has also been linked to cardiovascular disease (123).
Telomere length is a predictor of cardiovascular events (118),
and reduced leukocyte telomere length is associated with all-
cause mortality in patients with stable coronary disease (123). A
relationship has also been shown between telomere length and
PWV (124). Interestingly, statin therapy appears to increase
telomere length and improve survival (118).
Shorter telomeres have been detected in senescent endothe-
lial cells and vascular smooth muscle cells from human athero-
sclerotic plaques (125–128). Furthermore, shorter telomeres
have been found in endothelial cells in patients with coronary
artery disease compared with those from age-matched patients
without coronary disease, and in atherosclerotic coronary
endothelial cells compared with those from nonatherosclerotic
sites (126). Senescent cells promote endothelial dysfunction and
hence atherosclerosis, and appear to be implicated in plaque
destabilization (127, 128).
Animal models of telomerase deficiency result in progressive
telomere shortening and consequent cell senescence, and de-
velop premature aging-associated disorders including athero-
sclerosis, cardiac dysfunction, and sudden death (129, 130).
These studies suggest that endothelial dysfunction and senes-
cence induced by telomere shortening may play a critical role in
coronary atherogenesis.
Therefore, accelerated aging, characterized by shortening of
the DNA component of telomeres, might cause vascular and
pulmonary disease via mechanisms we have already discussed,
such as increased systemic inflammation, connective tissue
destruction, and endothelial dysfunction.
Accelerated aging processes may therefore be the link for
the association between COPD and increased cardiovascular
risk.
EFFECTS OF TREATMENT ON CARDIOVASCULAR
END POINTS
Emerging evidence of the important consequences of the sys-
temic effects of COPD, particularly adverse cardiovascular
effects, has led to consideration of potential therapies directed
at these systemic effects. Since it has been considered, but not yet
proven, that systemic inflammation is a mechanism for the
increased risk of cardiovascular disease in COPD, this has pro-
vided the rationale to consider using novel therapeutic interven-
tions that target this response, either directly or indirectly by
reducing lung inflammation (131). There is circumstantial evi-
dence, but as yet no clinical trial which has demonstrated that
treating systemic or lung inflammation in COPD reduces cardio-
vascular morbidity or mortality.
There is no evidence that the potential antiinflammatory
effects of bronchodilators, either b-agonists or anticholinergics
or theophyllines, have any effect on the systemic inflammation
and consequent risk of cardiovascular disease.
Inhaled corticosteroids have the potential to reduce systemic
inflammation. An initial report in a small number of subjects
suggested that 2 weeks of treatment with inhaled (fluticasone
500 mg twice daily) or oral corticosteroids (prednisolone 30 mg/d)
could suppress systemic CRP levels by 50 and 63%, respectively,
compared with placebo (132), and that this reduction might be
linked with decreased cardiovascular events. However, a much
larger randomized placebo-controlled trial failed to demonstrate
any significant effect of 4 weeks of treatment with inhaled
corticosteroids alone or in combination with long-acting b-
agonists on CRP or IL-6 levels (133).
The effect of inhaled corticosteroids on the risk of acute
myocardial infarction has been studied in a cohort of patients
with COPD from the Saskatchewan health services database. In
MacNee, Maclay, and McAllister: Cardiovascular Disease in COPD 829
this retrospective study, the use of inhaled corticosteroids (ICS)
overall was not associated with a significant decrease in the risk
of acute myocardial infarction (134). However, a 32% reduction
in the risk of myocardial infarction was observed for low doses
of ICS (50–200 mg/d) (134).
Statins have been shown to decrease mortality from cardio-
vascular disease and to lower CRP levels, probably because
they also reduce the production of IL-6 (135). Experimentally,
simvastatin inhibited cigarette smoking–induced emphysema
and reduced the inflammatory-cell infiltrate in the lungs (136).
Retrospective pharmaco-epidemiologic studies have also in-
dicated that statins reduce hospitalizations from exacerbations,
acute coronary events, and cardiovascular and respiratory mor-
tality among patients with COPD (137), and the combined use of
statins and ICSs is associated with a more favorable prognosis
than the use of a statin alone (138). A randomized controlled trial
of the effects of statins in COPD is now needed.
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